Overall market sentiment has been high on Thermogenesis Holdings Inc (THMO) stock lately. THMO receives a Bullish rating from InvestorsObserver's Stock Sentiment Indicator.
What is Stock Sentiment?
Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score.
As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend.
Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down.
InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend.
Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.
What's Happening With THMO Stock Today?
Thermogenesis Holdings Inc (THMO) stock is down -11.14% while the S&P 500 has risen 1.75% as of 3:24 PM on Monday, Feb 1. THMO is lower by -$0.38 from the previous closing price of $3.41 on volume of 1,343,497 shares. Over the past year the S&P 500 has risen 16.32% while THMO is lower by -39.52%. THMO lost -$3.78 per share in the over the last 12 months.
More About Thermogenesis Holdings Inc
ThermoGenesis Holdings, Inc. develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. The Company currently markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally-closed CAR-TXpressâ?¢ platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market.